Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2024 08:00 ET | Source: IN8bio, Inc

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
April 16, 2024 16:05 ET | Source: IN8bio, Inc

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 09, 2024 16:30 ET | Source: IN8bio, Inc

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
March 14, 2024 16:00 ET | Source: IN8bio, Inc

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
March 05, 2024 16:30 ET | Source: IN8bio, Inc

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
February 14, 2024 08:00 ET | Source: IN8bio, Inc

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a...
January 04, 2024 08:00 ET | Source: IN8bio, Inc

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored trial of INB-100 at the 65th American...
December 11, 2023 16:05 ET | Source: IN8bio, Inc

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy,...
December 11, 2023 09:00 ET | Source: IN8bio, Inc

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations Proceeds to...
December 07, 2023 08:00 ET | Source: IN8bio, Inc

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist...